SCHEMBL18362014

SCHEMBL18362014

CCOC(=O)CN1C(=O)CCc2c(Oc3cc(C#N)ncn3)cccc21

nearest known ligand 0.57

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ LOXL2 Q9Y4K0 3/20 0.57
▸ NPSR1 Q6W5P4 1/20 0.40
▸ LMNA P02545 3/20 0.38
▸ ALDH1A1 P00352 3/20 0.36
▸ POLB P06746 1/20 0.36
▸ GAA P10253 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ HTT P42858 2/20 0.36
▸ USP2 O75604 1/20 0.36
▸ MAPT P10636 2/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ CYP1A2 P05177 1/20 0.34
▸ CYP2C9 P11712 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18362005 0.85 LOXL2 (0.77) LOXL2NPSR1LMNAALDH1A1L3MBTL1
SCHEMBL19755831 0.82 LOXL2 (0.62) LOXL2NPSR1LMNAALDH1A1L3MBTL1
SCHEMBL18362120 0.80 LOXL2 (0.49) LOXL2
SCHEMBL18361800 0.80 LOXL2 (0.57) LOXL2NPSR1LMNAALDH1A1L3MBTL1
SCHEMBL18050034 0.79 LOXL2 (0.76) LOXL2NPSR1LMNAALDH1A1HTT
SCHEMBL18362158 0.78 LOXL2 (0.46) LOXL2LMNAPOLBUSP2
SCHEMBL18072429 0.77 LOXL2 (0.54) LOXL2NPSR1LMNAALDH1A1L3MBTL1
SCHEMBL19755828 0.76 LOXL2 (0.80) LOXL2NPSR1LMNAALDH1A1HTT
SCHEMBL19739498 0.73 LOXL2 (0.54) LOXL2NPSR1LMNAHTTMEN1
SCHEMBL19755832 0.73 NPSR1 (0.55) LOXL2NPSR1LMNAALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180186755-A1 LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF PHARMAKEA INC (US) 2018-07-05 — — US disclosed
US-20180186755-A1 LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF PHARMAKEA INC (US) 2018-07-05 — — US disclosed
US-20180186755-A1 LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF PHARMAKEA INC (US) 2018-07-05 — — US disclosed
WO-2017003862-A1 LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF PHARMAKEA, INC. (US) 2017-01-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180186755-A1 LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF LOXL2, LOXL1, LOX LOXL2 1/4885NPSR1 3951/4885LMNA 179/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback